Compound Amino Acid Granules (9AA)

This product can supplement the body's essential amino acids, significantly increase protein synthesis and improve nutritional status. In chronic renal failure, the plasma concentration of most essential amino acids in the body decreases, while the plasma concentration of non-essential amino acids is normal or increased. This product can restore the decreased plasma concentration of essential amino acids. If sufficient energy is supplied at the same time, assimilation can be enhanced, so that protein does not need to be decomposed and utilized as energy, and no or very little nitrogen terminal metabolites are produced, which is beneficial to alleviate the symptoms of uremia. It corrects calcium and phosphorus metabolism disorders.

Isoleucine 0.406g, leucine 0.638g, lysine hydrochloride 0.0.464g, methionine 0.638g, phenylalanine 0.638g, threonine 0.29g, tryptophan 0.145g, valine 0.4727g, histidine hydrochloride 0.319g.

This product is white or off-white granules.

Used for non-end-stage chronic renal failure, etc.

Oral administration, once a day, 1 bag at a time or swallow or drink with water as directed by your doctor.

Not yet clear.

1. Patients with amino acid metabolism disorder are prohibited from using this product. 2. Patients with severe liver damage, heart failure and edema are prohibited from using this product. 3. Patients who are allergic to Livzon Pharmaceutical Compound Amino Acid Granules (AA) are prohibited from using this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Drug interactions may occur if used with other drugs. Please consult your pharmacist or doctor for details.

seal.

3.45g (total amino acids)

24 months

Livzon Pharmaceutical Grouping Limin Pharmaceutical FACTORY

• Founded in:

  1997-05-24

• Address:

  No. 89, Gongye West Road, Shaoguan City, Guangdong

• Tax NO.:

  91440200618357941C

• Registered Funds:

  61.56101 million yuan

• Email:

  Log in to view